NEW YORK, NY -- (Marketwired) -- 12/16/14 -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) securities between April 21, 2014 and October 27, 2014.
For more information, click here: http://zlk.9nl.com/sareptatherapeutics.
The complaint alleges that the Company made false and/or misleading statements and/or failed to disclose to investors that: (a) the Company failed to provide sufficient data for its New Drug Application submission for marketing approval of eteplirsen, and (b) that as a result, the Application would likely be filed in mid-2015, rather than in 2014.
If you suffered a loss in Sarepta you have until February 6, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/sareptatherapeutics.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits and have helped shareholders recover millions of dollars in losses over the years. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (866) 367-6510
www.zlk.com
